Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What is the Projected CAGR for the Coagulation Factor Deficiency Market Size from 2025 to 2034?
There has been robust enlargement observed in the size of the coagulation factor deficiency market in the past few years. The market is projected to surge from $4.58 billion in 2024 to $4.93 billion in 2025, with a compound annual growth rate of 7.7%. This growth in the previous years can be linked to various factors such as a higher incidence of hemophilia, the development of recombinant factors, increasing knowledge about coagulation disorders, an improvement in diagnostic abilities, government assistance for uncommon diseases, the advent of prophylactic therapies, augmentation of patient registries and augmented investment in the biotechnology sector.
In the upcoming years, the coagulation factor deficiency market is projected to witness significant expansion, with an expected worth of$6.58 billion in 2029 and a compound annual growth rate (CAGR) of 7.5%. This anticipated growth during the forecast period can be linked to the increased application of gene therapies, a heightened focus on personalized medicine, the escalating incidence of coagulation disorders, broadening access in emerging markets and the integration of digital health solutions, along with continuous advancements in biomanufacturing technologies. Leading trends expected to shape the forecast period involve gene editing techniques like CRISPR, the creation of long-acting recombinant factors, progress in gene therapy delivery mechanisms, wearable devices that monitor coagulation, artificial intelligence utilization for treatment optimization, diagnostic tools available at the point-of-care, drug delivery via nanoparticles, the development of recombinant products that are free from plasma, innovating biosimilars, and the incorporation of precision medicine methodologies.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21152&type=smp
What are the Fundamental Drivers and Innovations Shaping the Coagulation Factor Deficiency Market?
The escalation in the number of blood-related disorder cases is anticipated to drive the expansion of the coagulation factor deficiency market. Blood-related conditions are a set of disorders affecting the creation, operation, or makeup of blood cells, platelets, or plasma, leading to ailments such as anemia, clotting troubles, or immune deficiencies. The rising occurrences of these conditions are attributed to aging population demographics, genetic predilections, growing consciousness, environmental elements, changing lifestyles, mounting chronic disease incidences and advancements in diagnostic tech that permit earlier detection. Coagulation factor deficiency aids in managing blood disorders by supplying much-needed clotting factors to inhibit or regulate excessive bleeding in situations like hemophilia, where the body’s inherent clotting ability is compromised. Notably, as per a 2024 report by the Leukemia and Lymphoma Society, an American professional organization, one person is diagnosed with leukemia, lymphoma or myeloma in the US every 3 minutes, with an estimated 187,740 individuals being diagnosed with these cancers, making up 9.4% of the expected 2,001,140 new cancer cases. Additionally, as reported by the National Health Service (NHS) England in May 2024, around 17,000 people in England are living with sickle cell disease, a hereditary blood disorder, with about 250 fresh cases diagnosed each year. This increase in blood-related disorders is fueling the coagulation factor deficiency market’s growth.
How Is the Coagulation Factor Deficiency Market Segmented?
The coagulation factor deficiencymarket covered in this report is segmented –
1) By Product: Recombinant Coagulation Factor Concentrates; Plasma-derived Coagulation Factor Concentrates; Biologics; Desmopressin; Other Product Types
2) By Deficiency Type: Haemophilia A; Hemophilia B; Von Willebrand Disease; Factor XI Deficiency; Factor XIII Deficiency; Other Treatment Types
3) By End Users: Hospitals; Clinics; Home Care; Other End Users
Subsegments:
1) By Recombinant Coagulation Factor Concentrates: Recombinant Factor VIII; Recombinant Factor IX; Recombinant Factor VIIa; Other Recombinant Factors
2) By Plasma-derived Coagulation Factor Concentrates: Plasma-derived Factor VIII; Plasma-derived Factor IX; Plasma-derived Factor VII; Other Plasma-derived Factors
3) By Biologics: Monoclonal Antibodies; Gene Therapy Products
4) By Desmopressin: Intravenous Desmopressin; Intranasal Desmopressin
5) By Other Product Types: Fresh Frozen Plasma (FFP); Prothrombin Complex Concentrates (PCC)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21152&type=smp
Which Regions Are Driving the Next Phase of the Coagulation Factor Deficiency Market Growth?
North America was the largest region in the coagulation factor deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the coagulation factor deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Coagulation Factor Deficiency Market?
Firms dominating the market for coagulation factor deficiency are concentrating on developing cutting-edge treatments like one-time gene therapy. This approach aims to offer enduring, or possibly curative results for individuals suffering from blood clotting disorders such as hemophilia, therefore limiting the need for perpetual infusions of clotting factors. One-time gene therapy is a type of treatment that manipulates the genetic material in a patient’s cells to treat or even eliminate a disease, intending to provide long-term or permanent therapeutic effects after a single application. For instance, in April 2024, U.S. pharmaceutical and biotech company, Pfizer Inc., reported that the U.S. Food and Drug Administration (FDA) approved BEQVEZ (fidanacogene elaparvovec-dzkt) for treating adults with moderate to severe hemophilia B on factor IX (FIX) prophylaxis therapy. As a stand-alone adeno-associated virus (AAV)-based gene therapy, it aims to integrate a functional FIX gene replica, encoding a high-activity FIX variant into the treated cells. This revolutionary gene therapy allows hemophilia B patients to self-produce FIX via this single-treatment protocol, eliminating the need for multiple FIX infusions.
View the full report here:
https://www.thebusinessresearchcompany.com/report/coagulation-factor-deficiency-global-market-report
How Is the Coagulation Factor Deficiency Market Defined and What Are Its Core Parameters?
Coagulation factor deficiency refers to a condition where the body lacks one or more clotting factors necessary for blood coagulation, leading to prolonged bleeding or difficulty in stopping bleeding. These deficiencies are treated with clotting factor concentrates and other therapies, which are used to manage and prevent bleeding episodes in patients with conditions like hemophilia.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21152
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model